Insider · CIK 0001007923

ZUERBLIS KENNETH J

Reports to the SEC for 4 companies · MORRIS PLAINS, NJ

sec.gov

Transactions

Companies

Filings

CIK

0001007923

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2020-06-10	STEMLINE THERAPEUTICS INCU Disposition from Tender	Director	UDisposition from Tender	−60.1K sh	—	—	0
2020-06-10	STEMLINE THERAPEUTICS INCStock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−34K sh	—	—	0
2020-06-10	STEMLINE THERAPEUTICS INCStock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−24K sh	—	—	0
2019-06-25	STEMLINE THERAPEUTICS INCA Award	Director	AAward	+15K sh	—	—	60,121
2018-06-21	STEMLINE THERAPEUTICS INCA Award	Director	AAward	+13.2K sh	—	—	45,121
2017-06-19	STEMLINE THERAPEUTICS INCA Award	Director	AAward	+10K sh	—	—	31,963
2017-06-19	STEMLINE THERAPEUTICS INCStock Options (right to buy)A Award	Director	AAward	+24K sh	—	—	24,000
2016-05-25	STEMLINE THERAPEUTICS INCStock Options (right to buy)A Award	Director	AAward	+34K sh	—	—	34,000
2015-06-23	STEMLINE THERAPEUTICS INCA Award	Director	AAward	+10K sh	—	—	21,963
2015-06-23	STEMLINE THERAPEUTICS INCStock Options (right to buy)A Award	Director	AAward	+24K sh	—	—	24,000
2014-09-02	STEMLINE THERAPEUTICS INCP Purchase	Director	PPurchase	+1,000 sh	$11.14	+$11.1K	11,963
2013-06-19	STEMLINE THERAPEUTICS INCStock Options (right to buy)A Award	Director	AAward	+20K sh	—	—	20,000
2013-05-30	STEMLINE THERAPEUTICS INCP Purchase	Director	PPurchase	+200 sh	$16.38	+$3,276	10,263
2013-05-30	STEMLINE THERAPEUTICS INCP Purchase	Director	PPurchase	+700 sh	$16.38	+$11.5K	10,963
2013-05-29	STEMLINE THERAPEUTICS INCP Purchase	Director	PPurchase	+600 sh	$15.85	+$9,509.94	8,563
2013-05-29	STEMLINE THERAPEUTICS INCP Purchase	Director	PPurchase	+500 sh	$15.86	+$7,930	9,063
2013-05-29	STEMLINE THERAPEUTICS INCP Purchase	Director	PPurchase	+1,000 sh	$15.86	+$15.9K	10,063
2012-02-01	SAVIENT PHARMACEUTICALS INCOption to Purchase Common Stock, $.01 par valueA Award	EVP, Chief Financial Officer	AAward	+100K sh	$2.26	+$226K	100,000
2011-12-07	IMMUNOMEDICS INCM Exercise/Conversion	Director	MExercise/Conversion	+5,000 sh	—	—	9,167
2011-12-07	IMMUNOMEDICS INCRestricted Stock UnitA Award	Director	AAward	+5,000 sh	—	—	5,000
2011-12-07	IMMUNOMEDICS INCStock Options (right to buy)A Award	Director	AAward	+10K sh	—	—	10,000
2011-11-18	SAVIENT PHARMACEUTICALS INCP Purchase	EVP, Chief Financial Officer	PPurchase	+2,000 sh	$2.35	+$4,690	7,000
2011-09-15	SAVIENT PHARMACEUTICALS INCP Purchase	EVP, Chief Financial Officer	PPurchase	+4,000 sh	$4.05	+$16.2K	5,000
2011-09-14	SAVIENT PHARMACEUTICALS INCP Purchase	EVP, Chief Financial Officer	PPurchase	+1,000 sh	$3.97	+$3,970	1,000
2011-09-12	SAVIENT PHARMACEUTICALS INCOption to Purchase Common Stock, $.01 par valueA Award	EVP, Chief Financial Officer	AAward	+300K sh	$3.81	+$1.14M	300,000
2010-12-01	IMMUNOMEDICS INCM Exercise/Conversion	Director	MExercise/Conversion	+4,167 sh	—	—	4,167
2010-12-01	IMMUNOMEDICS INCRestricted Stock UnitA Award	Director	AAward	+5,000 sh	—	—	5,000
2010-12-01	IMMUNOMEDICS INCStock Options (right to buy)A Award	Director	AAward	+10K sh	—	—	10,000
2004-02-06	ENZNViskase Holdings, Inc. · Employee Stock Option (Right To Buy)A Award	Chief Financial Officer	AAward	+50K sh	—	—	50,000
2004-02-06	ENZNViskase Holdings, Inc. · Restricted Stock UnitA Award	Chief Financial Officer	AAward	+12.5K sh	—	—	12,500
2002-07-01	ENZNViskase Holdings, Inc. · Common Stock (right to buy)A Award	Chief Financial Officer	AAward	+50K sh	—	—	50,000
2001-02-21	ENZNViskase Holdings, Inc.S Sale	Chief Financial Officer	SSale	−15K sh	$65.15	−$977K	—
2001-02-21	ENZNViskase Holdings, Inc.S Sale	Chief Financial Officer	SSale	−35K sh	$65.15	−$2.28M	2,600
2001-02-21	ENZNViskase Holdings, Inc. · Stock Option (a)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+15K sh	—	—	—
2001-02-21	ENZNViskase Holdings, Inc. · Stock Option (a)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+35K sh	—	—	—
2001-02-20	ENZNViskase Holdings, Inc.S Sale	Chief Financial Officer	SSale	−35K sh	$65.05	−$2.28M	—
2001-02-20	ENZNViskase Holdings, Inc.S Sale	Chief Financial Officer	SSale	−5,000 sh	$65.05	−$325K	—
2001-02-20	ENZNViskase Holdings, Inc. · Stock Option (a)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+35K sh	—	—	—
2001-02-20	ENZNViskase Holdings, Inc. · Stock Option (a)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+5,000 sh	—	—	—
2000-07-31	ENZNViskase Holdings, Inc. · Common Stock (a)A Award	Chief Financial Officer	AAward	+50K sh	—	—	—
2000-07-31	ENZNViskase Holdings, Inc. · Common Stock (a)A Award	Chief Financial Officer	AAward	+50K sh	—	—	—
2000-07-11	ENZNViskase Holdings, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+3,000 sh	$2.81	+$8,437.5	—
2000-07-11	ENZNViskase Holdings, Inc.S Sale	Chief Financial Officer	SSale	−3,000 sh	$53.75	−$161K	2,600
2000-07-10	ENZNViskase Holdings, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+20K sh	$10.63	+$213K	—
2000-07-10	ENZNViskase Holdings, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+5,000 sh	$4.88	+$24.4K	—
2000-07-10	ENZNViskase Holdings, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+40K sh	$3.50	+$140K	—
2000-07-10	ENZNViskase Holdings, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+12K sh	$2.81	+$33.8K	—
2000-07-10	ENZNViskase Holdings, Inc.S Sale	Chief Financial Officer	SSale	−20K sh	$53.88	−$1.08M	—
2000-07-10	ENZNViskase Holdings, Inc.S Sale	Chief Financial Officer	SSale	−5,000 sh	$53.94	−$270K	—
2000-07-10	ENZNViskase Holdings, Inc.S Sale	Chief Financial Officer	SSale	−35K sh	$53.94	−$1.89M	—

Recent filings

Accepted (ET)
Jun 104
ZUERBLIS KENNETH J0001104659-20-071825
SEC(opens sec.gov)
Jun 284
ZUERBLIS KENNETH J0001104659-19-038305
SEC(opens sec.gov)
Jun 224
ZUERBLIS KENNETH J0001104659-18-041872
SEC(opens sec.gov)
Jun 204
STEMLINE THERAPEUTICS INC0001104659-17-040454
SEC(opens sec.gov)
May 264
STEMLINE THERAPEUTICS INC0001104659-16-123688
SEC(opens sec.gov)
Jun 254
STEMLINE THERAPEUTICS INC0001104659-15-047708
SEC(opens sec.gov)
Sep 44
STEMLINE THERAPEUTICS INC0001104659-14-064672
SEC(opens sec.gov)
Jun 214
STEMLINE THERAPEUTICS INC0001104659-13-050783
SEC(opens sec.gov)
Jun 34
STEMLINE THERAPEUTICS INC0001104659-13-046275
SEC(opens sec.gov)
Feb 134
ZUERBLIS KENNETH J0001181431-12-007984
SEC(opens sec.gov)
Dec 94
ZUERBLIS KENNETH J0001209191-11-060555
SEC(opens sec.gov)

Companies

Address

C/O IMMUNOMEDICS INC. 300 AMERICAN ROAD

MORRIS PLAINS, NJ, 07950